
India's quest for cooking gas shifts from east to west
The negotiations, happening against the backdrop of the US tariff on Indian goods, support the target set by both countries earlier this year to increase their energy trade to $20 billion. This would include India importing liquified petroleum gas (LPG) from the US through term contracts, and increasing crude oil and liquefied natural gas (LNG) imports.
'Indian OMCs are in talks, collectively, with at least a dozen LPG suppliers in the US. The negotiations are for supplies starting January next year, and the discussions are progressing well," one of the three people cited above said. The person added that although deals may be signed separately, given that talks are happening at a combined level, the nature of deals would be largely the same.
Targa, OneOk
Some of the major American LPG suppliers are Texas-headquartered Targa Resources and Enterprise Products and Oklahoma-headquartered ONEOK. Queries emailed to the Union ministries of petroleum and commerce, the Indian oil marketing companies, and the US LPG suppliers went unanswered.
India traditionally imports most of its LPG from West Asian countries including Qatar, the UAE and Saudi Arabia through long-term contracts, while other major LPG importing countries source it from the US. The US so far has been supplying India LPG in small volumes through spot deals, and this is the first time the Indian companies may have a term deal with US suppliers. On the other hand, China has been a major buyer of LPG from the US.
In India, LPG is used primarily for residential cooking, followed by commercial and industrial purposes. India imported LPG worth $12.47 billion in FY25, 19.85% higher than $10.42 billion the previous year. According to Ken Research, as of December 2024, the Indian LPG market was valued at $15 billion, with growth backed by the government's emphasis on use of LPG for cooking purposes through the Pradhan Mantri Ujjwala Yojana.
Thaw?
The talks with the US firms is seen as indicating a thaw in ties between the two, even as talks on the Bilateral Trade Agreement remain active but are stuck on intractable issues such as dairy and agriculture. US president Donald Trump has also wared that India could face penalties if it continues purchasing petroleum products from Russia.
"India is a huge importer of LPG. US is a large producer of LPG which is produced as natural gas liquids along with shale gas. So, US can be a significant supplier of LPG to India," said Prashant Vasisht, senior vice president and co-group head, corporate ratings, ICRA Ltd. He added the price of LPG will not be very different and will be competitive compared to the West Asian LPG on a landed basis in India.
In a bid to diversify import sources amid geopolitical tensions and regional instability in West Asia, Indian buyers are already forging new ties. State-run BPCL signed an annual contract with Norway's Equinor to secure 550 kilotonne per annum of propane and butane, reducing its reliance on the West Asian countries. Reuters last month reported that India plans to source about 10% of its cooking gas imports from the US as part of a broader effort to boost energy purchases to narrow its trade gap with Washington.
Trade war ripples
In March this year, as the tariff war flared between the US and China, a report by maritime consultancy Drewry suggested that if the US-China trade war escalated, Saudi contract prices could attract a premium, with China likely engaging Middle Eastern suppliers and forcing India to diversify its import sources, including the US.
LPG used in India comprises 60% butane and 40% propane. West Asian exports are better suited for this as they are primarily butane-dominated, since their LPG production is a byproduct of oil processing. On the other hand, US supplies are primarily propane-dominated, as LPG production in the US is the byproduct of natural gas processing. According to the Drewry report, Butane accounted for 52% of India's LPG imports in 2024.
"India may source the required propane from the US, which would be 40-50% of the composition and the butane may continued to be imported from the Gulf countries," an industry executive said on the condition of anonymity
LPG country
As on 1 April, 2025, the three state-run oil marketing companies which dominate the LPG market in India, together have 32.97 crore active LPG customers in the domestic category who are being served by 25,542 LPG distributors. Data from the Petroleum Planning & Analysis Cell (PPAC) shows these companies sold nearly 31.2 million metric tonnes of LPG in FY25, out of which about 88.3% was sold in the domestic sector.
Ajay Srivastava, former Indian Trade Service officer and founder of the Global Trade Research Initiative (GTRI), said, 'Those engaging with US oil firms for the deal should ensure certainty of supply and competitive pricing, as the US has overcommitted to supplying oil and gas to various countries, but currently lacks adequate production of petroleum products and LNG. The contract must guarantee supply certainty and include penalties for failure to deliver on time."
However, a former government official, requesting anonymity, said, 'It's a forward-looking move by both sides, as such deals happen with the consent of the government, and this move could help ease tensions and make it easier to resolve some of the sticking points in the larger agreement."
Vessel dynamics
The Drewry report cited earlier said the increase in import of American LPG would also impact the LPG vessel segments that India employs to import the product. Typically, India uses medium gas carriers (MGC) to transport LPG, as the country has low storage capacities and most terminals are unable to cater to very large gas carriers (VLGCs) However, upgrading the infrastructure as well as changing supplier countries can lead to changes in the vessel employment patterns with VLGCs increasing their share in India's import mix with higher imports from the US.
India's energy imports from the US, largely crude, have already witnessed an uptick this year. To be sure, India has already assured the US that it would ramp up energy ties and increase imports. After Prime Minister Narendra Modi's meeting with Trump last month in Washington, foreign secretary Vikram Misri had said that India aims to increase its purchases of US energy in the near future. During prime minister Narendra Modi's visit to the US in February, the US president Donald Trump said that both the countries have reached an 'important" agreement on energy that would make the US one of the leading suppliers of oil and gas to India, 'hopefully number one supplier".
Mint earlier reported that oil and gas imports are emerging as a key factor in the ongoing bilateral trade talks between the US and India and India plans to increase the share of Western Texas Intermediate or WTI crude in the country's import basket, which could even entail setting a tariff rate quota for US crude.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
22 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'


Hans India
25 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.


NDTV
25 minutes ago
- NDTV
Trump Says US China Close To Trade Agreement, Will Meet Xi If Deal Is Struck
President Donald Trump said on Tuesday the US was close to a trade deal with China and that he would meet his Chinese counterpart Xi Jinping before the end of the year if an agreement is struck. "He asked for a meeting, and I'll end up having a meeting before the end of the year most likely, if we make a deal. If we don't make a deal, I'm not going to have a meeting," Trump told CNBC in an interview referring to China's Xi. "We're getting very close to a deal. We're getting along with China very well," Trump said. Treasury Secretary Scott Bessent said last week he believed the US had the "makings of a deal" with China after officials from the two countries met in Stockholm in a bid to resolve economic disputes aimed at extending their truce on a trade war by three months. China is facing an August 12 deadline to reach a durable tariff agreement with the US administration, after Beijing and Washington reached preliminary deals in May and June to end escalating tit-for-tat tariffs and a cut-off of rare earth minerals. Without a deal, global supply chains could face renewed turmoil from US duties snapping back to triple-digit levels that would amount to a bilateral trade embargo. Speaking to CNBC, Trump also said his administration would soon impose tariffs on US imports of pharmaceuticals, semiconductors and chips, which is expected to impact China.